

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer
[ID4000]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • EQRx (aumolertinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • EGFR Positive UK • Cancer Black Care • Cancer Equality • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Lung Cancer Coalition <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • Association of Surgeons of Great Britain and Ireland • Association for Cancer Surgery • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Thoracic Oncology Group • British Thoracic Society • Cancer Research UK • Health Lumen • Lung Cancer Nursing UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (gefitinib) • AstraZeneca (gefitinib, osimertinib) • Boehringer Ingelheim (afatinib) • Cipla EU (gefitinib) • Genus Pharmaceuticals (gefitinib) • Glenmark Pharmaceuticals Europe (erlotinib, gefitinib) • Mylan (erlotinib) • Pfizer (dacomitinib) • Roche (erlotinib) • Sandoz (erlotinib, gefitinib) • Tillomed Laboratories (erlotinib) • Zentiva (erlotinib, gefitinib)

Final stakeholder list for the single technology appraisal of aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer ID4000

Issue date: December 2021

© National Institute for Health and Care Excellence 2021. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • National Heart and Lung Institute • Primary Care Respiratory Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS North Derbyshire CCG • NHS Thurrock CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Association of Lung Research • Cochrane Airways Group • Cochrane Lung Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.